Use of trimetazidine in ischemic heart disease

Abstract

Abstract: Ischemic heart disease (IHD) is characterized pathologically by the atheromatous plaque which may induce stenosis or obstruction of the coronary arterial lumen leading to myocardial ischemia, experienced by the patients as chest pain.Plaque rupture provides a focus for platelet deposition and thrombosis, and results in unstable angina or myocardial infarction.Stable angina pectoris is treated conventionally by using beta blockers, nitrates and calcium channel blockers (CCB), all of which act by either increasing the supply or decreasing the demand of oxygen in myocardium.In recent years a group of drugs known as metabolic modulators have been particularly shown to be beneficial in protecting the myocardium.Trimetazidine has been a special target in this group.It has been found that in ischemic myocardium there is high rate of fatty acid (FA) oxidation and subsequent inhibition of glucose oxidation.This drug is thought to have direct cytoprotective action in ischemic myocardium through inhibition of the oxidation of FA.Numerous studies are still being carried out to further clarify its roles in various other conditions related directly or indirectly with IHD.The purpose of the review was to assimilate the results of various trials done all over the world in the recent years to find out the role in IHD and the exact mechanism of action, in order to know its true worth in myocardial protection.

Key words: trimetazidine, metabolic modulator, ischemic heart disease

CLC Number:

R541.4

Acharya Dhan Kumar, DANG Yu-hua. Use of trimetazidine in ischemic heart disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(4): 385-391.

References

1 Kantor PF, Lucien A, Kozak R, Lopaschuk GD.The antianginal drug trimetazidine shifts cardiac energy metabolism from FA oxidation to glucose oxidation by inhibiting mitochondrial longchain 3-ketoacyl coenzyme A thiolase[J].Circ Res, 2000;86: 580-8
2 Lopaschuk GD, Barr R, Thomas PD, Dyck JRB.Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long chain 3-ketoacyl coenzyme A thiolase[J].Circ Res, 2003;93:E33
3 Trimetazidine:A well tolerated and novel alternative in stable angina pectoris[J].Drug Ther Perspect, 2000;16:1-5
4 Parker JO.Chronic angina pectoris:Inadequecies of current therapy[J].Am J Geriatr Cardiol, 2004;13:261-6
5 MarzilliM, KleinWW.Efficacy and tolerability of trimetazidine in stable angina:a meta-analysis of randomized, double blind, controlled trials [J].Coron Artery Dis, 2003;14:171-9
6 Lee L, Horowitz J, Frenneaux M.Metabolic manipulation in ischemic heart disease, a novel approach to treatment[J].Eur Heart J, 2004;25:634-41
7 Lopaschuk GD.Inhibiting FA oxidation as a novel therapeutic approach to treating ischemic heart disease[J].Cardiovasc J S Afr, 2004;15:S1
8 Shlyakhto EV, Almazov VV, Nifontov EM, Vakhrameyeva IV, Rudomanov OG, Zakharov DV, et al.Antianginal effects of trimetazidine and left ventricular function improvement in patients with stable angina pectoris[J].Am J Cardio Drugs, 2002;2: 119-24
9 Makolkin VI, Osadchly KK.Trimetazidine modified release in the treatment of stable angina[J].Clin Drug Invest, 2004;24: 731-8
10 Parker JO.Angina pectoris:a review of current and emerging therapies[J].Am J Manag Care, 2004;10:S332-8
11 Pauly DF, Pepine CJ.Ischemic heart disease:Metabolic Approaches to Management[J].Clin Cardiol, 2004;27:439-41
12 Ruzyllo W, Szwed H, Sadowski Z, Elikowski W, Grzelak-Szafranska H, Orszulak W, et al.Efficacy of trimetazidine in patients with recurrent angina:a subgroup analysis of the TRIMPOL II study[J].Curr Med Res Opin, 2004;20:1447-54
13 Detry JM, Leclercq PJ.Trimetazidine European multicenter study versus propranolol in angina pectoris: contribution of Holter electrocardiographic ambulatory monitoring [J].Am J Cardiol, 1995;76:8B-11B
14 Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamkarz A, Orszulak W, et al.Combination treatment in stable effort angina using trimetazidine and metoprolol.Results of a randomized, double-blind, multicentre study(TRIMPOL II) [J]. Eur Heart J, 2001;22:2267-74
15 Manchanda SC, Krishnaswami S.Combination treatment with trimetazidine and diltiazem in stable angina pectoris[J].Heart, 1997;78:353-7
16 Manchanda SC.Treatment of stable angina with low dose diltiazem in combination with the metabolic agent trimetazidine[J]. Int J Card Imaging, 2003;88:83-9
17 Koylan N, Bilge AK, Adalet K, Mercanoglu F, Buyukozturk K, TTS group.Comparision of the effects of trimetazidine and diltiazem on exercise performance in patients with coronary heart disease.The Turkish trimetazidine study (TTS) [J].Acta Cardiol, 2004;59:644-50
18 Chazov EI, Lepakchin VK, Zharova EA, Fitilev SB, Levin AM, Rumiantzeva EG, et al.Trimetazidine in angina combination therapy-the TACT study:trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo controlled, multicenter study [J].Am J Ther, 2005;12:35-42
19 Karpov RS, Koshel, Skaia OA, Chernov VI, Ocheredko NA, Efimova EV, et al.Clinical efficacy of combination therapy with trimetazidine and angiotensin converting enzyme inhibitors in patients with hypertension and ischemic heart disease associated with type II diabetes[J].Kardiologiia, 2004;44:43-7
20 Szwed H.Clinical benefits of trimetazidine in patients with recurrent angina[J].Coron Artery Dis, 2004;15:S17-21
21 The emip-fr group.Effect of 48-h intravenous trimetazidine on short-and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy.A doubleblind, placebo-controlled, randomized trial[J].Eur Heart J, 2000;21:1537-46
22 Rogacka D, Guzik P, Wykretowicz A, Rzezniczak J, Dziarmaga M, Wysocki H, et al.Effects of trimetazidine on clinical symptoms and tolerance of exercise of patients with syndrome X: a preliminary study[J].Coron Artery Dis, 2000;11:171-7
23 Vitale C, WajngatenM, Sposato B, Gebara O, Rossini P, Fini M, et al.Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease [J].Eur Heart J, 2004;25:1814-21
24 Essop MF, Opie LH.Metabolic therapy for heart failure[J]. Eur Heart J, 2004;25:1765-8
25 Fragasso G, Piatti PM, Monti L, Palloshi A, Setola E, Pucetti P, et al.Short-and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy[J].Am Heart J, 2003;146:E18
26 Rosano GMC, Vitale C, Sposato B, Mercuro G, FiniM.Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease:a double-blind placebo-controlled study[J].Cardiovasc Diabetol, 2003;2:16
27 Korantzopoulos P, Kountouris E, Siogas K, Galaris D.The potential benefits of trimetazidine in patients with diabetes and ischemic cardiomyopathy[J].Am Heart J, 2004;148:E31
28 Morillas P, Hernandez A, Pallares V, Bertomeu V, Roldan FJ, Capdevilla C, et al.Usefulness of trimetazidine in ischemia-reperfusion lesion.Experimental study in myocardial stunning model[J].Arch Cardiol Mex, 2004;74:262-70
29 Baumert H, Faure JP, Zhang K, Petit I, Goujon JM, Dutheil D, et al.Evidence for a mitochondrial impact of trimetazidine during cold ischemia and reperfusion[J].Pharmacology, 2004; 71:25-37
30 Barsotti A, Di Napoli P.Trimetazidine and cardioprotection during ischemia-reperfusion[J].Ital Heart J, 2004;5:29S-36S

[1]	SHENG Yang, ZHANG Tianjie. Effects of trimetazidine on serum-homocysteine and serum-gamma-glutamyl transferase level in the cases of stable angina cordis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 922-926.
[2]	YANG Liu, GUO Yi. Updating the evidence for the effect trimetazidine and shexiang baoxin pills on chronic heart failure: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(6): 644-650.
[3]	ZHU Gang-yan, XU Hong-xin, TIAN Yi-hao, MA Hong-mei, TANG Shi-qi, WANG Fu-liang, WU Song-lin. Ameliorative effects of trimetazidine on bone marrow mesenchymal stem cells viability through Bcl-2 expression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(7): 729-735.
[4]	XIE Ming-Ming, WANG Xin-Fang, ZHU Xiang-Ming, YANG Ya, LU Qing, CHEN Li-Xin, NIE Shao-Ping, JIANG Jue-Quan, CAO Lin-Shen. Effects of transmyocardial laser revascularization combined with basic fibroblast growth factor on myocardial viability and cardiac function in dog models with acute myocardial ischemia¹ [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(2): 149-154.
[5]	SHAN Shou-Jie, CHEN Shao-Liang. Transplantation of marrow stem cell on ischemic heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(5): 473-476.
[6]	DAI Zhen-Lin, DUAN Bao-Xiang, LI Jian-Chun. Clinical anti-ischemic effects of trimetazidine in the treatment of stable angina [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2001, 6(4): 343-345.